stoxline Quote Chart Rank Option Currency Glossary
  
Rigel Pharmaceuticals, Inc. (RIGL)
1.2  -0.03 (-2.44%)    04-12 16:00
Open: 1.21
High: 1.24
Volume: 3,746,263
  
Pre. Close: 1.23
Low: 1.18
Market Cap: 210(M)
Technical analysis
2024-04-12 4:51:52 PM
Short term     
Mid term     
Targets 6-month :  1.69 1-year :  1.89
Resists First :  1.45 Second :  1.62
Pivot price 1.33
Supports First :  1.17 Second :  0.98
MAs MA(5) :  1.23 MA(20) :  1.34
MA(100) :  1.29 MA(250) :  1.23
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  11.1 D(3) :  15.4
RSI RSI(14): 34.8
52-week High :  1.96 Low :  0.7
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RIGL ] has closed above bottom band by 14.4%. Bollinger Bands are 10.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.24 - 1.25 1.25 - 1.26
Low: 1.16 - 1.17 1.17 - 1.18
Close: 1.19 - 1.2 1.2 - 1.21
Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Headline News

Fri, 12 Apr 2024
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Cross Above 200-Day Moving Average of $1.19 - Defense World

Wed, 10 Apr 2024
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire

Thu, 04 Apr 2024
Market Sentiment Around Loss-Making Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Simply Wall St

Fri, 08 Mar 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Simply Wall St

Thu, 07 Mar 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 175 (M)
Shares Float 147 (M)
Held by Insiders 2 (%)
Held by Institutions 61.4 (%)
Shares Short 4,940 (K)
Shares Short P.Month 3,500 (K)
Stock Financials
EPS -0.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.16
Profit Margin -21.7 %
Operating Margin 5.2 %
Return on Assets (ttm) -10.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -27.7 %
Gross Profit (p.s.) 0
Sales Per Share 0.66
EBITDA (p.s.) -0.12
Qtrly Earnings Growth -48 %
Operating Cash Flow -6 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -8.58
PEG Ratio -0.4
Price to Book value -7.51
Price to Sales 1.81
Price to Cash Flow -36.67
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android